Metabolomics profile of patients treated with gemcitabine
Conditions
Interventions
Patients who are planned for treatment with gemcitabine by their treating oncologist, will be approached for study participation. The interventions in this study are limited to additional blood draws
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Age = 18 years 2. Able to understand the written information and able to give informed consent 3. Planned gemcitabine treatment (intravenous).
Exclusion criteria
Exclusion criteria: Unable to draw blood for study purposes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the changes in the metabolomic profile of patients with solid tumors at the end of gemcitabine infusion. | — |
Secondary
| Measure | Time frame |
|---|---|
| To analyze the metabolomic profile of patients with solid tumors prior to gemcitabine infusion.To investigate whether the timing of blood sample withdraw affects the metabolomic profile of patients with solid tumors treated with gemcitabine when the assay is performed.To quantify the impact of gemcitabine treatment on the metabolomic profile of patients with solid tumors. | — |
Countries
Netherlands
Contacts
Public ContactS. Bins
Erasmus MC, Universitair Medisch Centrum Rotterdam
Outcome results
None listed